322 related articles for article (PubMed ID: 2502419)
1. CD8+CD11b+ peripheral blood T lymphocytes contain lymphokine-activated killer cell precursors.
Dianzani U; Zarcone D; Pistoia V; Grossi CE; Pileri A; Massaia M; Ferrarini M
Eur J Immunol; 1989 Jun; 19(6):1037-44. PubMed ID: 2502419
[TBL] [Abstract][Full Text] [Related]
2. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets.
Ochoa AC; Hasz DE; Rezonzew R; Anderson PM; Bach FH
Cancer Res; 1989 Feb; 49(4):963-8. PubMed ID: 2521457
[TBL] [Abstract][Full Text] [Related]
3. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells.
Tilden AB; Itoh K; Balch CM
J Immunol; 1987 Feb; 138(4):1068-73. PubMed ID: 3100627
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
Kalland T; Belfrage H; Bhiladvala P; Hedlund G
J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
[TBL] [Abstract][Full Text] [Related]
5. Human CD3 gamma delta + activated lymphocytes exhibit killer activity in vitro against autologous leukemic cells.
Bensussan A; Lagabrielle JF; Castaigne S; Boisson N; Miclea JM; Benbunan M; Degos L
Nouv Rev Fr Hematol (1978); 1989; 31(2):129-32. PubMed ID: 2528119
[TBL] [Abstract][Full Text] [Related]
6. A novel functional cell surface dimer (Kp43) expressed by natural killer cells and T cell receptor-gamma/delta+ T lymphocytes. I. Inhibition of the IL-2-dependent proliferation by anti-Kp43 monoclonal antibody.
Aramburu J; Balboa MA; Ramírez A; Silva A; Acevedo A; Sánchez-Madrid F; De Landázuri MO; López-Botet M
J Immunol; 1990 Apr; 144(8):3238-47. PubMed ID: 1691231
[TBL] [Abstract][Full Text] [Related]
7. CD3+4-8-WT31-(T cell receptor gamma+) cells and other unusual phenotypes are frequently detected among spontaneously interleukin 2-responsive T lymphocytes present in the joint fluid in juvenile rheumatoid arthritis. A clonal analysis.
De Maria A; Malnati M; Moretta A; Pende D; Bottino C; Casorati G; Cottafava F; Melioli G; Mingari MC; Migone N
Eur J Immunol; 1987 Dec; 17(12):1815-9. PubMed ID: 2961576
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 2-activated human killer cells are derived from phenotypically heterogeneous precursors.
Damle NK; Doyle LV; Bradley EC
J Immunol; 1986 Nov; 137(9):2814-22. PubMed ID: 2944965
[TBL] [Abstract][Full Text] [Related]
9. In vitro generation and antitumor activity of adherent lymphokine-activated killer cells from the blood of patients with brain tumors.
Whiteside TL; Wang YL; Selker RG; Herberman RB
Cancer Res; 1988 Nov; 48(21):6069-75. PubMed ID: 2971433
[TBL] [Abstract][Full Text] [Related]
10. Lysis of tumor cells by CD3+4-8-16+ T cell receptor alpha beta- clones, regulated via CD3 and CD16 activation sites, recombinant interleukin 2, and interferon beta 1.
van de Griend RJ; Tax WJ; van Krimpen BA; Vreugdenhil RJ; Ronteltap CP; Bolhuis RL
J Immunol; 1987 Mar; 138(5):1627-33. PubMed ID: 2949018
[TBL] [Abstract][Full Text] [Related]
11. Major histocompatibility complex-unrestricted cytolytic activity of human T cells. Analysis of precursor frequency and effector phenotype.
Patel SS; Thiele DL; Lipsky PE
J Immunol; 1987 Dec; 139(11):3886-95. PubMed ID: 3500232
[TBL] [Abstract][Full Text] [Related]
12. Morphologic and functional characterization of human peripheral blood T cells expressing the T cell receptor gamma/delta.
Ferrini S; Zarcone D; Viale M; Cerruti G; Millo R; Moretta A; Grossi CE
Eur J Immunol; 1989 Jul; 19(7):1183-8. PubMed ID: 2527156
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the functional capabilities of CD3+CD4-CD8- and CD3+CD4+CD8+ human T cell clones.
Patel SS; Wacholtz MC; Duby AD; Thiele DL; Lipsky PE
J Immunol; 1989 Aug; 143(4):1108-17. PubMed ID: 2526180
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-2- and mitogen-activated NK-like killer cells from highly purified human peripheral blood T cell (CD3+ N901-) cultures.
Atzpodien J; Wisniewski D; Gulati S; Welte K; Knowles R; Clarkson B
Nat Immun Cell Growth Regul; 1987; 6(3):129-40. PubMed ID: 3114621
[TBL] [Abstract][Full Text] [Related]
15. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC
Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412
[TBL] [Abstract][Full Text] [Related]
16. In vivo antitumor activity of anti-CD3-induced activated killer cells.
Yun YS; Hargrove ME; Ting CC
Cancer Res; 1989 Sep; 49(17):4770-4. PubMed ID: 2527087
[TBL] [Abstract][Full Text] [Related]
17. Two-color flow cytometry and functional analysis of lymphocytes cultured from human renal allografts: identification of a Leu-2+3+ subpopulation.
Preffer FI; Colvin RB; Leary CP; Boyle LA; Tuazon TV; Lazarovits AI; Cosimi AB; Kurnick JT
J Immunol; 1986 Nov; 137(9):2823-30. PubMed ID: 3093583
[TBL] [Abstract][Full Text] [Related]
18. Clonal analysis of CD4-CD8- human thymocytes expressing a T cell receptor gamma/delta chain. Direct evidence for the de novo expression of CD8 surface antigen and of cytolytic activity against tumor targets.
Mingari MC; Varese P; Bottino C; Melioli G; Moretta A; Moretta L
Eur J Immunol; 1988 Nov; 18(11):1831-4. PubMed ID: 2974427
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM
Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959
[TBL] [Abstract][Full Text] [Related]
20. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells.
Maghazachi AA; Vujanovic NL; Herberman RB; Hiserodt JC
J Immunol; 1988 Apr; 140(8):2846-52. PubMed ID: 3258622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
